Endolytix
Endolytix Technology, Inc is developing innovative therapeutics to combat antibiotic resistance in nontuberculous mycobacterial infections and tuberculosis. The company focuses on targeted drug delivery to treat intracellular bacteria effectively, addressing a significant global health challenge with a biological approach that leverages specificity, catalytic capability, and low toxicity.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical enzyme-based therapeutic candidates with macrophage-targeted delivery
Preclinical-stage therapeutic candidates comprising enzyme-based bactericidal payloads formulated into targeted delivery vehicles designed to reach and kill intracellular mycobacteria.
Preclinical enzyme-based therapeutic candidates with macrophage-targeted delivery
Preclinical-stage therapeutic candidates comprising enzyme-based bactericidal payloads formulated into targeted delivery vehicles designed to reach and kill intracellular mycobacteria.
Services
Preclinical R&D services including targeted-delivery formulation, in vitro macrophage infection assays, and efficacy testing of enzyme-based therapeutics.
Preclinical R&D services including targeted-delivery formulation, in vitro macrophage infection assays, and efficacy testing of enzyme-based therapeutics.
Expertise Areas
- Intracellular pathogen targeting
- Mycobacterial therapeutics
- Enzymatic antimicrobial agent development
- Liposomal and encapsulation delivery strategies
Key Technologies
- Enzymatic antibacterial cocktails
- Liposomal encapsulation
- Macrophage infection assays
- Fluorescence co-localization microscopy
News & Updates
Participation in the conference held in Fort Collins, CO, USA.
Research article on targeting intracellular mycobacteria.
Research article on enzyme delivery for mycobacterial infections.
Participation in the conference held in Fort Collins, CO, USA.
Research article on targeting intracellular mycobacteria.
Research article on enzyme delivery for mycobacterial infections.